Results 71 to 80 of about 1,053,768 (311)

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy

Acta Pharmaceutica Sinica B, 2020
Accurate tumor targeting, deep penetration and superb retention are still the main pursuit of developing excellent nanomedicine. To achieve these requirements, a stepwise stimuli-responsive strategy was developed through co-administration tumor ...
Congcong Lin, Fan Tong, Rui Liu, Rou Xie, Ting Lei, Yuxiu Chen, Zhihang Yang, Huile Gao, Xiangrong Yu   +8 more
doaj   +1 more source

Lambda phage nanoparticles for targetomics [PDF]

, 2012
The emerging aim of drug delivery requires the bioactive or therapeutic molecule to be protected from degradation and reach its target cell and intracellular location.
Ghaemi, A., Gill, P., Gorji, A., Soleimanjahi, H., Tabaraei, A.   +4 more
core   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Supramolecular Nano‐Grid Platform to Load and Deliver Liposomes and Exosomes

Small Structures
In general, carriers are designed to deliver pharmaceutical (featuring small drug‐molecules) and biopharmaceutical (featuring large‐molecule drugs, e.g., antibodies, proteins, etc.) active ingredients and platform that is capable of transporting ...
Jing Li, Wuzhen Ma, Xiaohong Ren, Tao Guo, Boyang Yang, Chenxi Huang, Ting Xiong, Yuhua Guo, Zeru Li, Siwen Wang, Bingqian Jia, Shujun Wang, Li Wu, Jiwen Zhang   +13 more
doaj   +1 more source

Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma

Acta Pharmaceutica Sinica B, 2019
Due to the critical correlation between inflammation and carcinogenesis, a therapeutic candidate with anti-inflammatory activity may find application in cancer therapy.
Xi Cao, Ying Hu, Shi Luo, Yuejing Wang, Tao Gong, Xun Sun, Yao Fu, Zhirong Zhang   +7 more
doaj   +1 more source

Poly(lactic-co-glycolic) acid drug delivery systems through transdermal pathway : an overview [PDF]

, 2017
In past few decades, scientists have made tremendous advancement in the field of drug delivery systems (DDS), through transdermal pathway, as the skin represents a ready and large surface area for delivering drugs.
AE Porter, AK Kohli, B Hafner, CJ Ke, DP Bottaro, E Garcia-Garcia, F Ajalloueian, F Stracke, G Jin, J Luengo, J Panyam, JH Park, JM Antonini, KF Soto, L Jacob, L Xiao, N Li, P Kocbek, PS Korrapati, R Alvarez-Romn, R Dinarvand, R Langer, R Langer, R Qi, R Sridhar, RF Donnelly, S Acharya, S Takenaka, T Xia, U Bilati, V Petkov, XS Wu, Y Zhang, YK Demir, YK Luu, Z Zhang, ZX Meng, ZX Meng   +37 more
core   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh

Acta Pharmaceutica Sinica B, 2016
A phospholipid-based injectable gel was developed for the sustained delivery of leuprolide acetate (LA). The gel system was prepared using biocompatible materials (SPME), including soya phosphatidyl choline (SPC), medium chain triglyceride (MCT) and ...
Danhong Long, Tao Gong, Zhirong Zhang, Rui Ding, Yao Fu   +4 more
doaj   +1 more source